A colorectalis daganatra ma már igen heterogén betegségként tekintünk, mely heterogenitást a kialakulásában szerepet játszó genetikai faktorok, molekuláris eltérések, különböző jelátviteli útvonalak, valamint mikro- és makrokörnyezeti tényezők okoznak. A korábban ismert „klasszikus” adenoma-carcinoma szekvencia mellett az elmúlt évtizedben egy másik, alternatív útvonal is felismerésre került. Ezt „fogazott” útvonalnak nevezzük, mely az elváltozások kb. egyharmadáért felelős. Ezek a laesiók a molekuláris tulajdonságaikon felül makroszkópos és mikroszkópos képükben és progressziós hajlamukban, illetve prognózisukban is eltérnek a klasszikus útvonal daganataitól. Az alábbi összefoglaló közlemény ezen eltérések molekuláris tulajdonságait, makroszkópos és szövettani jellegzetességeit, illetve klinikai jelentőségét szemlélteti. Orv Hetil. 2018; 159(6): 206–214.
Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319: 525–532.
JE IJ, Medema JP, Dekker E. Colorectal neoplasia pathways: state of the art. Gastrointest Endosc Clin N Am. 2015; 25: 169–182.
Imamura Y, Lochhead P, Yamauchi M, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer 2014; 13: 135.
Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012; 22: 271–282.
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007; 67: 2643–2648.
Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113–130.
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23: 609–618 .
Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28: 466–474.
Wong IH. Methylation profiling of human cancers in blood: molecular monitoring and prognostication (review). Int J Oncol. 2001; 19: 1319–1324.
Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta 2012; 1825: 77–85.
Moussata D, Boschetti G, Chauvenet M, et al. Endoscopic and histologic characteristics of serrated lesions. World J Gastroenterol. 2015; 21: 2896–2904.
Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330–337.
Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21: 1350–1356.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767.
Zoratto F, Rossi L, Verrico M, et al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. Tumour Biol. 2014; 35: 6195–6206.
Bosman FT, Yan P. Molecular pathology of colon cancer. Pol J Pathol. 2014; 65(Suppl 1): S1–S11.
Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017; 17: 79–92.
O’Brien MJ. Hyperplastic and serrated polyps of the colorectum. Gastroenterol Clin North Am. 2007; 36: 947–968.
Bae JM, Kim JH, Kang GH. molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. Arch Pathol Lab Med. 2016; 140: 406–412.
Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th edn. International Agency for Research on Cancer, Lyon, 2010.
Bettington M, Walker N, Clouston A, et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013; 62: 367–386.
Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012; 107: 1315–1329.
Rex DK, Ulbright TM. Step section histology of proximal colon polyps that appear hyperplastic by endoscopy. Am J Gastroenterol. 2002; 97: 1530–1534.
Jass JR. Hyperplastic polyps of the colorectum – innocent or guilty? Dis Colon Rectum 2001; 44: 163–166.
Langner C. Serrated and non-serrated precursor lesions of colorectal cancer. Dig Dis. 2015; 33: 28–37.
Bettington M, Walker N, Rosty C, et al. Critical appraisal of the diagnosis of the sessile serrated adenoma. Am J Surg Pathol. 2014; 38: 158–166.
Singh R, Zorrón Cheng Tao Pu L, Koay D, et al. Sessile serrated adenoma/polyps: Where are we at in 2016? World J Gastroenterol. 2016; 22: 7754–7759.
IJspeert JE, Bastiaansen BA, van Leerdam ME, et al. Development and validation of the WASP classification system for optical diagnosis of adenomas, hyperplastic polyps and sessile serrated adenomas/polyps. Gut 2016; 65: 963–970.
Bateman AC. Pathology of serrated colorectal lesions. J Clin Pathol. 2014; 67: 865–874.
Bettington ML, Chetty R. Traditional serrated adenoma: an update. Hum Pathol. 2015; 46: 933–938.
Chetty R. Traditional serrated adenoma (TSA): morphological questions, queries and quandaries. J Clin Pathol. 2016; 69: 6–11.
Bettington ML, Walker NI, Rosty C, et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol. 2015; 28: 414–427.
Yamane L, Scapulatempo-Neto C, Reis RM, et al. Serrated pathway in colorectal carcinogenesis. World J Gastroenterol. 2014; 20: 2634–2640.
Rhee YY, Kim KJ, Kang GH. CpG island methylator phenotype-high colorectal cancers and their prognostic implications and relationships with the serrated neoplasia pathway. Gut Liver 2017; 11: 38–46.
Samadder NJ, Vierkant RA, Tillmans LS, et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology 2013; 145: 348–356.
Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 2011; 71: 1263–1271.
Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015; 148: 77–87.e2.
Juo YY, Johnston FM, Zhang DY, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014; 25: 2314–2327.
Russo A, Bazan V, Agnese V, et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol. 2005; 16(Suppl 4): iv44–iv49.
Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 2010; 362: 1795–1803.
Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy – results of the complete adenoma resection (CARE) study. Gastroenterology 2013; 144: 74–80.
Pohl H, Robertson DJ. Colorectal cancers detected after colonoscopy frequently result from missed lesions. Clin Gastroenterol Hepatol. 2010; 8: 858–864.
Vecchione L, Jacobs B, Normanno N, et al. EGFR-targeted therapy. Exp Cell Res. 2011; 317: 2765–2771.
Burt RW. Diagnosing Lynch syndrome: more light at the end of the tunnel. Cancer Prev Res. (Phila.) 2012; 5: 507–510.
Graham DM, Coyle VM, Kennedy RD, et al. Molecular subtypes and personalized therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2016; 12: 141–150.
Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28: 3219–3226.
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372: 2509–2520.
Schlicker A, Beran G, Chresta CM, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012; 5: 66.
Bordaçahar B, Barret M, Terris B, et al. Sessile serrated adenoma: from identification to resection. Dig Liver Dis. 2015; 47: 95–102.
Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012; 143: 844–857.
Carethers JM, Murali B, Yang B, et al. Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. PLoS ONE 2014; 9: e100461.
Müller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016; 469: 125–134.